Anaplastic lymphoma kinase (ALK) was originally identified from a rare subtype of non-Hodgkin's lymphomas carrying t(2;5)(p23;q35) translocation, where ALK was constitutively activated as a result of a fusion with nucleophosmin (NPM). Aberrant ALK fusion proteins were also generated in inflammatory fibrosarcoma and a subset of non-small-cell lung cancers, and these proteins are implicated in their pathogenesis. Recently, ALK has been demonstrated to be constitutively activated by gene mutations and/or amplifications in sporadic as well as familial cases of neuroblastoma. Here we describe another mechanism of aberrant ALK activation observed in a neuroblastoma-derived cell line (NB-1), in which a short-form ALK protein (ALK del2-3 ) having a truncated extracellular domain is overexpressed because of amplification of an abnormal ALK gene that lacks exons 2 and 3. ALK del2-3 was autophosphorylated in NB-1 cells as well as in ALK del2-3 -transduced cells and exhibited enhanced in vitro kinase activity compared with the wild-type kinase. ALK del2-3 -transduced NIH3T3 cells exhibited increased colony-forming capacity in soft agar and tumorigenicity in nude mice. RNAi-mediated ALK knockdown resulted in the growth suppression of ALK del2-3 -expressing cells, arguing for the oncogenic role of this mutant. Our findings provide a novel insight into the mechanism of deregulation of the ALK kinase and its roles in neuroblastoma pathogenesis.
INTRODUCTION
Anaplastic lymphoma kinase (ALK) (OMIM: 105590) is an orphan receptor tyrosine kinase (RTK) that was initially characterized as a fusion partner of the nucleophosmin (NPM)-ALK chimeric protein associated with the t(2;5)(p23;q35) translocation in anaplastic large-cell lymphoma.
1,2 Subsequent studies have revealed that various ALK-containing fusion proteins with different fusion partners are generated in various solid tumors, such as inflammatory myofibroblastic tumors, non-small-cell lung cancer and squamous cell carcinoma of the esophagus. 3 --6 Furthermore, recent genome-wide studies have revealed that ALK is activated by gene amplification and nucleotide mutations and is involved in the pathogenesis of both familial and sporadic neuroblastoma. 7 --10 Neuroblastoma is an intractable, solid tumor of childhood arising from the neural crest and can arise anywhere along the sympathetic nervous system. 11 The overall 5-year survival rate for neuroblastoma is p40%, despite current intensive multimodality treatments. 12 --14 Considering that ALK mutations preferentially involve advanced neuroblastoma with a poor outcome, the more relevant implication of these findings is that ALK inhibitors may improve the clinical outcome of children suffering from intractable neuroblastoma.
In this study, we demonstrated another mechanism of aberrant ALK activation in neuroblastoma, in which an abnormal ALK gene with a deletion of exons 2 and 3 was amplified in a neuroblastoma-derived cell line (NB-1), leading to high-level expression of an ALK protein variant with a truncated extracellular domain ). Furthermore, we demonstrated that ALK del2-3 had constitutive kinase activity and showed a transforming capacity in NIH3T3 cells. Moreover, ALK inhibition experiments using small interfering RNA (siRNA)-mediated gene knockdown and the low-molecular-weight compound, TAE684, also supported the oncogenic role of ALK del2-3 . Our results will help elucidate the mechanism of aberrant activation of ALK kinase and the role of activated ALK in the pathogenesis of neuroblastoma.
RESULTS

Detection of a short-form ALK protein in NB-1 cells
To examine the status of ALK in neuroblastoma, western blotting analysis was performed with a panel of 24 neuroblastoma-derived cell lines (Table 1) . Among the 24 samples examined, the NB-1 cell line showed high-level expression of an ALK protein having a low molecular weight of 208 kDa compared with the molecular weight of 220 kDa for the wild-type protein ( Figure 1a ). Subsequent sequencing and reverse transcription --polymerase chain reaction (RT --PCR) analysis of ALK messages from NB-1 cells revealed the presence of an aberrant ALK transcript with a 285-bp in-frame deletion in the 5 0 region corresponding to exons 2 and 3 ( Figures  1b and c) , which should result in the production of an abnormal ALK protein with a truncated N-terminal extracellular domain. Using a primer set for exons 2 and 3, a 166-bp product was also detected in NB-1 cells, indicating the presence of the wild-type ALK allele in NB-1 cells (Figures 1b and c) . The deletion spanned 224 --318 amino acids (aa), including the N-terminal end of the first meprin A5 protein and receptor protein tyrosine phosphatase mu (MAM) domain (aa 264 --427) (Figure 1d) . 15, 16 We analyzed fulllength ALK cDNAs isolated from 71 primary neuroblastoma samples for possible nucleotide deletions using RT --PCR (Table 2) , but no deletions were detected.
Structural abnormality of the ALK gene in NB-1 cells As reported previously, 7 our single-nucleotide polymorphism array-based copy number analysis of NB-1 cells disclosed highlevel gene amplification of the ALK-containing 2p24 segment. This should explain the high ALK expression observed in this cell line (Figures 1a and b) . In particular, the genomic copy numbers within the 2p23 amplicon exhibited a transient decrease at three consecutive single-nucleotide polymorphisms (Chr2: 29 911 541 --29 912 210), which corresponded to ALK intron 3, raising the possibility that a gene deletion involving exons 2 and 3 was responsible for the aberrant ALK transcript (Figure 2a) . To confirm this, we performed Southern blot analysis of NB-1 genomic DNA using fragments exons 1 --4 as probes ( Figure 2b ). As shown in Figures 2c --e, Southern blot analysis confirmed ALK gene amplification in NB-1 cells, as these blots showed high-intensity signals for each of the four ALK-specific probes in NB-1 cells compared with those in the controls. However, a significant difference was observed in the signal intensity between the fragments containing exons 1/4 and exons 2/3 in the NB-1 lanes, in which exons 1 and 4 showed 3.9-and 3.8-fold higher signals than exons 2 and 3, respectively. This result was confirmed by quantitative genomic PCR analysis using seven primer sets located within ALK exons 1 --4 ( Figure 2f ). Taken together, these results indicate that the 2p23 amplicons were heterogeneous with regard to the species of ALK it contained, among which the predominant ALK allele had a deletion at exons 2 and 3, and these amplicons were responsible for the generation of ALK del2-3 .
Oncogenic potential of an aberrant short-form ALK protein We next evaluated the oncogenic role of the truncated form of ALK found in NB-1 cells in terms of its kinase activity. As shown in Figure 3a , ALK del2-3 was strongly phosphorylated in NB-1 cells, whereas the wild-type ALK expressed in NH-12 cells was unphosphorylated. Similar to the constitutive active F1174L ALK mutant when expressed in NIH3T3 cells, ALK del2-3 had enhanced ALK phosphorylation compared with wild-type ALK (Figure 3b) . Moreover, after anti-FLAG immunoprecipitation of FLAG-tagged ALK constructs, ALK del2-3 and F1174L ALK mutants were strongly phosphorylated according to western blot analysis using a PY20 blot (Figure 3c ). In addition, they exhibited enhanced kinase activity in an in vitro kinase assay using the YFF peptide as a substrate (Figure 3d ). To confirm kinase activity of the ALK del2-3 mutant, we further examined in vitro kinase activities of wild-type and mutant ALK-expressing NIH3T3 cells using a universal substrate. The immunoprecipitated FLAG-tagged ALK del2-3 mutant showed significantly increased kinase activity (Supplementary Figure S1) .
In an analysis of activated downstream signaling, significantly enhanced STAT3 phosphorylation was observed in ALK del2-3 and F1174L mutants, whereas a significant increase in AKT phosphorylation was not detected in any samples (Figure 3e and Supplementary Figure S2 ). Extracellular regulated kinase (ERK) was probably phosphorylated in the F1174L mutant and wild-type ALK, but not in ALK del2-3 ( Figure 3e ). The results of three independent experiments were quantified by densitometric scanning (Supplementary Figure S2) .
We investigated the oncogenic potential of the ALK del2-3 mutant in NIH3T3 cells, in terms of colony formation in soft agar and tumor generation in nude mice. As shown in Figures 4a and b (Figure 4c ).
ALK
del2-3 was retained in the endoplasmic reticulum Among ALK signaling pathway molecules, STAT3 was only strongly phosphorylated by ALK del2-3 , suggesting that the ALK del2-3 mutant was exclusively involved in the STAT3 pathway. It has been previously reported that intracellular fms-like tyrosine kinase-internal tandem duplication activation induces an aberrant downstream signaling outcome. 17 To determine whether ALK del2-3 expresses at the cell surface and mediates signals from endoplasmic reticulum (ER), we analyzed localization and deglycosidation of ALK del2-3 in NB-1 cells and wild-type ALK in NH-12 cells. Immunofluorescence staining revealed that ALK in NB-1 cells was almost colocalized with PDI, whereas ALK in NH-12 cells was largely located at the plasma membrane ( Figure 5a ). As shown in Supplementary Figure S4 , colocalization of ALK and PDI was quantified using the Pearson's correlation coefficient. Moreover, to determine whether ALK del2-3 was subjected to maturation of its oligosaccharides, we examined the endoglycosidase H sensitivity of ALK expressed in NB-1 and NH-12 cells. As shown in Figure 5b , ALK del2-3 in NB-1 cells revealed the high sensitivity of endoglycosidase H compared with the wild-type ALK in NH-12 cells, suggesting that intercellular localization of ALK del2-3 was associated with a defect in N-linked glycosylation. 18 These results indicate that ALK del2-3 is mainly located at ER and aberrantly activates the STAT3 pathway from there.
Effect of ALK inhibition on cell growth in NB-1 cells Finally, we examined the effect of ALK inhibition on NB-1 cell proliferation using the small-molecule ALK inhibitor TAE684 and siRNA-mediated ALK knockdown. NB-1 cell growth was effectively inhibited by TAE684 with a half maximal inhibitory concentration (IC 50 ) of 13 nM, which was similar to the IC 50 for SK-N-SH (49 nM; an ALK-mutated TAE684-sensitive neuroblastoma cell line), but substantially lower than the IC 50 for TGW cells with the ALK 
Abbreviations: ALK, anaplastic lymphoma kinase; WT, wild type. 
DISCUSSION
Deregulated activation of ALK has been implicated in various human cancers through either generation of fusion proteins, overexpression or single amino-acid changes. In this study, we described a novel mechanism of oncogenic activation of ALK that operated in a neuroblastoma-derived cell line, NB-1. In NB-1 cells, an aberrant form of ALK that lacks exons 2 and 3 was amplified, leading to high-level expression of an N-terminal-truncated kinase, ALK del2-3 , and our functional studies confirmed the oncogenic role of ALK del2-3 . First, ALK del2-3 underwent autophosphorylation in NB-1 and NIH3T3 cells and demonstrated enhanced kinase activity, promoting downstream signaling pathways such as the STAT3 pathway. Second, ALK del2-3 promoted colony formation in soft agar and tumorigenicity when transduced into NIH3T3 cells in nude mice. Finally, inhibition of cell growth was observed when we treated NB-1 cells with TAE684, an ALK-specific kinase inhibitor, and siRNA-mediated gene knockdown. Unfortunately, screening of 71 primary neuroblastoma specimens and 23 neuroblastoma-derived cell lines did not identify a similar mechanism of ALK oncogenic activation in neuroblastoma; therefore, it is not a common mechanism for ALK activation in neuroblastoma. Nevertheless, the discovery of this unique ALK form will add to our knowledge with regard to the pathogenesis of neuroblastoma and will help to elucidate the mechanism of ALK activation.
Abnormal activation of RTK through a deletion in its extracellular domain has been documented in several cancers. 19 --21 A common example of abnormal RTK activation is the epidermal growth factor receptor class III variant, which is present in a substantial proportion of malignant gliomas and other human cancers, but completely absent in normal tissues. 22, 23 This variant results from a transcript having an 801-bp in-frame deletion of EGFR that corresponds to exons 2 --7, which leads to the generation of a protein with a truncated extracellular domain. 21, 24 Several molecular mechanisms have been implicated in the oncogenic pathway with epidermal growth factor receptor class III variant downstream signaling. 21, 24 For example, in addition to ligand-independent self-dimerization, epidermal growth factor receptor class III variant has been shown to constitutively interact with adaptor proteins SHC and GRB2, which are involved in the recruitment of the RAS pathway. 25 The recepteur d'origine nantais (RON) RTK variant with a deletion in the first immunoglobulinplexin transcription domain (ROND160) has also been considered as a constitutively activated kinase in several human cancers. 20, 26 RON belongs to the MET proto-oncogene family, which plays a critical role in epithelial cell homeostasis and tumorigenic development. 27 ROND160 is derived from a RON mRNA transcript by alternative splicing that eliminates 109 aa residues from the extracellular domain of RON b-chain and is expressed in 450% of primary colon cancers and 90% of brain tumors, but not in any normal tissues. 26, 28 The deleted 109 aa residues are encoded by exons 5/6, which constitute the first immunoglobulin-plexin transcription domain in the RON b-chain. 26, 28 The mechanism for the oncogenic activation of ROND160 is believed to be one in which the deletion in the extracellular domain causes conformational changes in the kinase and leads to spontaneous dimerization, which in turn causes constitutive receptor phosphorylation and increased intracellular signaling activation. 26, 28, 29 The ALK del2-3 variant consists of a 282-bp in-frame deletion of ALK that corresponds to 224 --318 aa in the first MAM domain (Figure 1d) . ALK is the sole RTK that contains MAM domains in its extracellular region. 30 Although MAM domains are thought to participate in cell--cell interactions, their significance in ALK function remains unclear. 15, 16 Thus, the functional significance of MAM deletion in the truncated ALK is still elusive. As the deleted region of ALK detected in NB-1 cells is in close proximity to a ligandbinding domain (391--401 aa), this deletion may structurally alter the ligand-binding domain. Similar to epidermal growth factor receptor class III variant and ROND160, the ALK del2-3 variant may be constitutively activated in a ligand-independent manner and/or through spontaneous dimerization, although the exact mechanism of constitutive activation of ALK del2-3 is yet to be elucidated. Oncogenic ALK transformation is mediated by interactions with downstream molecules that trigger a substantial intercellular signaling cascade. 31 The most relevant and best-characterized ALK downstream pathways are the RAS-ERK, JAK3-STAT3 and PI3K-AKT pathways. 31 Among ALK signaling molecules, STAT3 is only strongly phosphorylated by ALK del2-3 , suggesting that besides F1174L or K1062M ALK mutants, 7 ALK del2-3 would be exclusively involved in the STAT3 pathway. Recently, it has been reported that the oncogenic mutant of fms-like tyrosine kinase-internal tandem duplication aberrantly activates STAT5 when localized at ER, but fails to activate MAPK and AKT signaling. 17 Thus, this raises the possibility that involvement of the STAT3 pathway in ALK del2-3 -expressing cells resembles the fms-like tyrosine kinase-internal tandem duplication mutant. 17 Immunofluorescence staining and the endoglycosidase H sensitivity assay revealed that ALK del2-3 is mainly located at ER and aberrantly activates the STAT3 pathway from ER. Taken together, our results suggest that intracellular activation of ALK del2-3 switches downstream signaling to the ALK pathway. 18 Furthermore, ERK phosphorylation was similarly elevated in cells expressing wild-type or F1174L ALK. This may have been because of enhanced expression of exogenous wild-type ALK by retrovirusmediated gene transfer. Schulte et al. 32 reported that the high level of wild-type ALK and mutant ALK expression has similar effects on the neuroblastoma biological phenotype, which may be related to tumor growth. Taken together, the results from our study and from the study by Schulte et al. 32 suggest that in addition to the ALK mutants, elevated wild-type ALK expression also mediates similar molecular functions that contribute to the malignant phenotype in neuroblastoma.
In summary, we found that an N-terminal-truncated ALK protein observed in a neuroblastoma-derived cell line (NB-1) is a novel oncogenic isoform of ALK. This study provides a better understanding of the molecular mechanism of pathogenesis of neuroblastoma as well as oncogenic roles of ALK pathway.
MATERIALS AND METHODS Specimens
In all, 24 neuroblastoma cell lines were used in this study ( Table 1 ). The SCMC-N series was established in our laboratory. 33 The SJNB series and UTP-N-1 cells were provided by Dr AT Look and Dr A Inoue, respectively. Other cell lines were obtained from the Japanese Cancer Resource Cell Bank (http://cellbank.nibio.go.jp/wwwjcrbj.htm). All cells were maintained in RPMI 1640 medium (Gibco, Grand Island, NY, USA) supplemented with 10% fetal bovine serum in a humidified atmosphere containing 5% CO 2 at 37 1C. Primary neuroblastoma specimens were obtained through surgery or biopsy from patients who were diagnosed with neuroblastoma and who were admitted to Tokyo University Hospital, Saitama Children's Medical Center or various other hospitals between November 1993 and October 2006. The patients were staged according to the International Neuroblastoma Staging System, 34 and the clinicopathological findings are listed in Table 2 .
ALK expression analyses
Total cellular proteins were resolved on a 5 --10% gradient sodium dodecyl sulfate --polyacrylamide gel and electrophoretically transferred onto Abbreviations: ALK, anaplastic lymphoma kinase; ND, not determined.
Aberrant ALK activation by a novel truncated form J Okubo et al polyvinylidene difluoride membranes. After blocking with 5% milk in Trisbuffered saline containing 0.1% Tween (10 mM Tris--HCl (pH 7.4), 150 mM NaCl and 0.1% Tween-20), membranes were incubated for 1 h with primary antibody in TBS-T, washed and incubated for 12 h with primary antibody in 3% bovine serum albumin. The membranes were then washed again and incubated with anti-rabbit immunoglobulin G at room temperature for 1 h. Subsequently, they were extensively washed, and the proteins were visualized by enhanced chemiluminescence (Millipore, Bedford, MA, USA). Total RNA was extracted from the 24 cell lines and 71 frozen stocked tumors using Isogen reagent (Nippon Gene, Osaka, Japan) according to the manufacturer's instructions; the total RNA was analyzed by RT --PCR to synthesize cDNA using the SuperScript Preamplification System for firststrand cDNA synthesis (Life Technologies Inc., Rockville, MD, USA). RT --PCR analysis for ALK expression was performed as described previously, 7 using the primer sets listed in Table 3 . cDNA concentration was equalized using b-actin expression as a control.
Southern blot analysis
High-molecular-weight DNA was prepared from cells according to standard procedures using the QIAamp DNA Mini kit (Qiagen, Valencia, CA, USA) and a modification of the protocol provided by the manufacturer. DNA was extracted from NB-1 cells and peripheral normal blood cells. For Southern blot analysis, 10 mg genomic DNA was restricted with EcoRI and loaded onto an agarose gel. 35 After electrophoresis, the DNA was transferred to polyvinylidene difluoride membranes and hybridized with radiolabeled probes for ALK exons 1 --4 listed in Table 3 . The signal intensity of each band was quantified and calculated using the ImageQuant 400 and ImageQuant TL software version 7 (GE Healthcare, Piscataway, NJ, USA).
Quantitative genomic PCR analysis
Quantitative genomic real-time PCR was performed using SYBR Greenbased quantification (Bio-Rad Laboratories, Hercules, CA, USA). The standard curve method was used to calculate the target genome numbers in the NB-1 cell line. The relative target copy number was normalized to normal human genomic DNA as a calibrator. The primer sequences used for quantitative genomic PCR are shown in Table 3 .
Transforming potential of ALK mutants
ALK
WT -FLAG and ALK
F1174L
-FLAG were FLAG-tagged cDNAs for wild-type ALK and its F1174L mutant, respectively. FLAG-tagged cDNA for the deletion mutant (ALK del2-3 -FLAG) was isolated from total RNA of NB-1 cells by high-fidelity PCR. After re-sequencing, each cDNA was constructed into the pcDNA3 expression plasmid and transfected into NIH3T3 cells using Effectene Transfection Reagents (Qiagen, Tokyo, Japan). Kinase assays were performed with stable clones in these constructs. For western blot analysis of mutant ALK and colony formation assays, NIH3T3 cells were stably transduced with wild-type and mutant ALK by retrovirus-mediated gene transfer. FLAG-tagged cDNA for wild-type and mutated ALK were then Functional analyses of a short-form ALK To evaluate the phosphorylation status of the ALK mutants, stable clone cell lysates were subjected to western blot analysis with anti-ALK and the antibody-specific pTyr1604 (Cell Signaling Technology, Danvers, MA, USA) of ALK. Immunoprecipitation with antibodies to FLAG (Sigma, St Louis, MO, USA) were subjected to western blot analysis with a generic antiphosphotyrosine antibody (PY20). Western blot analyses were also performed using anti-ERK1/2, anti-phospho-ERK1/2, anti-AKT, anti-phospho-AKT, anti-STAT3 and anti-phospho-STAT3 antibodies (Cell Signaling Technology). AKT and STAT3 phosphorylation signals were quantitated by densitometric scanning using the ImageQuant 400 and ImageQuant TL software version 7 (GE Healthcare). The in vitro kinase assay was performed with the synthetic YFF peptide (Operon Biotechnologies, Reutlingen, Germany), as described previously, 36 using stable clones in pcDNA vector constructs. We also used the in vitro kinase assay for wild-type and mutant ALK expression in NIH3T3 cells by retrovirus-mediated gene transfer using the poly-GluTyr peptide. Cell extracts were immunoprecipitated with anti-Flag antibody, and the expression was subjected to immunoblotting using anti-ALK antibody. ALK mutant kinase activity was measured using a nonradioactive isotope solid-phase enzyme-linked immunosorbent assay in the Universal Tyrosine Kinase Assay kit (Takara Bio, Osaka, Japan). Assays were performed in 40 mM Tris (pH 7.4), 20 mM MgCl 2 , 2 mM dithiothreitol and 0.1 mg/ml bovine serum albumin buffer.
Transforming potential of short-form ALK Figure 6 . Effect of ALK inhibition on NB-1 cell proliferation using the ALK inhibitor TAE684 and siRNA-mediated ALK knockdown. (a) NB-1 cell growth was effectively inhibited by TAE684, with an IC 50 similar to that for SK-N-SH (an ALK-mutated TAE684-sensitive neuroblastoma cell line), but substantially lower than that for NIH3T3 cells with no ALK expression. (b, c) Effect of RNAi-mediated ALK knockdown on cell proliferation in neuroblastoma cell lines expressing either the ALK del2-3 mutant (NB-1) or wild-type ALK (NH-12). Cell growth was measured using the Cell Counting kit-8 after knockdown experiments using ALK-specific siRNAs, negative control siRNAs or mock experiments, in which absorbance was measured in triplicate and averaged for each assay. The mean ± s.d. of the average absorbance in three independent knockdown experiments was plotted to draw the growth curves. Successful knock down of the ALK protein was confirmed by anti-ALK blots using a-tubulin blots as controls.
assay was performed in nude mice, in which 1.0 Â 10 7 NIH3T3 cells expressing wild-type ALK and ALK del2-3 mutant were injected by the calcium phosphate method. Tumor formation was evaluated 21 days after inoculation as described previously. 6 Immunofluorescence Cells were fixed for 10 min with 4% paraformaldehyde and washed three times with phosphate-buffered saline. After 1 h of blocking in phosphatebuffered saline containing 4% donkey serum and 0.1% Triton X-100/ phosphate-buffered saline, the cells were incubated for 2 h in the same buffer with polyclonal anti-ALK (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and monoclonal anti-PDI (Abcam, Cambridge, MA, USA), respectively. The cells were then washed three times with phosphate-buffered saline before and after incubation with anti-mouse IgG Alexa Fluor 488 and antirabbit IgG Alexa Fluor 594-conjugated secondary antibodies, respectively, (Invitrogen, Carlsbad, CA, USA). The cells were then mounted in Prolong Gold (Invitrogen). Confocal laser microscopy was performed using a Fluoview 10 000 confocal microscope (Olympus, Tokyo, Japan). Colocalization of ALK and PDI was quantified using the Pearson's correlation coefficient and determined through correlation analysis with a Fluoview 1000 software. 37 Deglycosylation of ALK with N-glycosidase F, N-glycosidase H and O-glycosidase Proteins from cell lysates obtained from neuroblastoma cell lines NB-1 and NH-12 were incubated with N-glycosidase F and endoglycosidase H for deglycosylation (New England Biolabs, Ipswich, MA, USA), following the manufacturer's instructions. 18 The samples were then used for immunoblotting with anti-ALK antibody. Signal intensities of bands in the lane endoglycosidase H were quantified by densitometric scanning using the ImageQuant 400 and ImageQuant TL software version 7.
ALK inhibition by an ALK inhibitor and siRNA-mediated knockdown in neuroblastoma cells A partial ALK-deleted neuroblastoma-derived cell line (NB-1), ALK-mutated neuroblastoma-derived cell lines (SK-N-SH and TGW) and a glioblastomaderived cell line (H4) were cultured with varying concentrations of the ALK inhibitor TAE684, 8 and cell growth was measured using the CellTiter-Glo Luminescent Cell Viability Assay (Promega, Tokyo, Japan). NIH3T3 cells were used as a control. The IC 50 value of TAE684 against NB-1 cells was calculated by nonlinear regression (variable slope) using the GraphPad Prism 5 software (GraphPad, La Jolla, CA, USA). NB-1 and NH-12 cells with wild-type ALK were transfected with either an ALK-specific siRNA or a nonspecific siRNA, as described previously. 7 To assess the effect of ALK knockdown on cell growth, cells were seeded in 96-well plates at a concentration of 1.0 Â 10 4 cells per well 24 h before transfection and assayed using the Cell Counting kit-8 (Dojindo, Kumamoto, Japan). We also performed an siRNA-mediated ALK knockdown cell proliferation assay using a cell counter and 6-well plates. These cells were seeded in 6-well plates at a concentration of 2.0 Â 10 5 cells per well 24 h before transfection. The number of cells was counted after 72 h using cytorecon (ECI, Tokyo, Japan). Abbreviations: ALK, anaplastic lymphoma kinase; RT --PCR, reverse transcription --polymerase chain reaction.
